Similar articles for PMID: 31410784

Year	Number of Results
1995	1
1996	2
1997	6
1998	1
1999	2
2000	1
2002	3
2003	3
2004	3
2005	4
2006	2
2007	3
2008	7
2009	3
2010	2
2011	3
2012	5
2013	5
2014	10
2015	6
2016	4
2017	9
2018	12
2019	13
2020	22
2021	10

1

The Role of Patient-Physician Communication on the Use of Hydroxyurea in Adult Patients with Sickle Cell Disease.

Jabour SM, Beachy S, Coburn S, Lanzkron S, Eakin MN. Jabour SM, et al. J Racial Ethn Health Disparities. 2019 Dec;6(6):1233-1243. doi: 10.1007/s40615-019-00625-5. Epub 2019 Aug 13. J Racial Ethn Health Disparities. 2019. PMID: 31410784 Free PMC article.

2

Proponent or collaborative: Physician perspectives and approaches to disease modifying therapies in sickle cell disease.

Bakshi N, Sinha CB, Ross D, Khemani K, Loewenstein G, Krishnamurti L. Bakshi N, et al. PLoS One. 2017 Jul 20;12(7):e0178413. doi: 10.1371/journal.pone.0178413. eCollection 2017. PLoS One. 2017. PMID: 28727801 Free PMC article.

3

Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision.

Creary S, Zickmund S, Ross D, Krishnamurti L, Bogen DL. Creary S, et al. BMC Res Notes. 2015 Aug 25;8:372. doi: 10.1186/s13104-015-1344-0. BMC Res Notes. 2015. PMID: 26303306 Free PMC article.

4

Shared decision making for hydroxyurea treatment initiation in children with sickle cell anemia.

Crosby LE, Shook LM, Ware RE, Brinkman WB. Crosby LE, et al. Pediatr Blood Cancer. 2015 Feb;62(2):184-185. doi: 10.1002/pbc.25124. Epub 2014 Oct 12. Pediatr Blood Cancer. 2015. PMID: 25308571 Free PMC article.

5

Development and evaluation of a patient empowerment video to promote hydroxyurea adoption in sickle cell disease.

LaVista JM, Treise DM, Dunbar LN, Ritho J, Hartzema AG, Lottenberg R. LaVista JM, et al. J Natl Med Assoc. 2009 Mar;101(3):251-7. doi: 10.1016/s0027-9684(15)30853-1. J Natl Med Assoc. 2009. PMID: 19331257

6

Hydroxyurea for the treatment of sickle cell disease.

Segal JB, Strouse JJ, Beach MC, Haywood C, Witkop C, Park H, Wilson RF, Bass EB, Lanzkron S. Segal JB, et al. Evid Rep Technol Assess (Full Rep). 2008 Mar;(165):1-95. Evid Rep Technol Assess (Full Rep). 2008. PMID: 18457478 Free PMC article. Review.

7

From trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea.

Sinha CB, Bakshi N, Ross D, Krishnamurti L. Sinha CB, et al. PLoS One. 2018 Jun 27;13(6):e0199375. doi: 10.1371/journal.pone.0199375. eCollection 2018. PLoS One. 2018. PMID: 29949647 Free PMC article.

8

A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.

Creary SE, Gladwin MT, Byrne M, Hildesheim M, Krishnamurti L. Creary SE, et al. Pediatr Blood Cancer. 2014 Jun;61(6):1068-73. doi: 10.1002/pbc.24931. Epub 2014 Jan 16. Pediatr Blood Cancer. 2014. PMID: 24436121 Clinical Trial.

9

Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease.

Smaldone A, Findley S, Bakken S, Matiz LA, Rosenthal SL, Jia H, Matos S, Manwani D, Green NS. Smaldone A, et al. Contemp Clin Trials. 2016 Jul;49:134-42. doi: 10.1016/j.cct.2016.06.004. Epub 2016 Jun 17. Contemp Clin Trials. 2016. PMID: 27327779 Free PMC article.

10

Improving Uptake of Hydroxyurea in Patients with Sickle Cell Disease: A Retrospective Study of a Clinic-based Change in Consenting Practices.

Smith AW, Bodas P, Sidebotham L, Weilnau J, Wildman B. Smith AW, et al. J Natl Med Assoc. 2019 Apr;111(2):169-175. doi: 10.1016/j.jnma.2018.09.004. Epub 2018 Oct 10. J Natl Med Assoc. 2019. PMID: 30314826

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed